Domont, France

Didier Legroux


Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1985-1987

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Didier Legroux: Pioneering Medicinal Chemistry

Introduction

Didier Legroux, located in Domont, France, is a notable inventor recognized for his significant contributions in the field of medicinal chemistry. With a portfolio of two patents, he has developed innovative chemical compounds aimed at the creation of new medicaments.

Latest Patents

His latest patents include the development of Isoquinoline derivatives and their preparation. This innovation focuses on Isoquinoline derivatives of specific formulas that are useful in synthesizing 1(2H)-isoquinolone. Another notable patent involves the process for the preparation of quinuclidine derivatives. In this process, 3-methylene quinuclidine is reacted with aluminum hydride in the presence of transition metal halides, yielding compounds that are valuable for medicinal uses.

Career Highlights

Throughout his career, Didier Legroux has made impactful strides in the pharmaceutical industry, particularly during his tenure with renowned companies such as Pharmuka Laboratoires and Synthelabo. His innovative research has significantly contributed to advancements in drug development.

Collaborations

Didier has collaborated with esteemed colleagues, including Jean-Claude Bondiou and Francoise Hodac, enhancing his contributions to the field of medicinal chemistry. These partnerships have facilitated the exchange of ideas, leading to novel discoveries and advancements.

Conclusion

In conclusion, Didier Legroux's work in medicinal chemistry exemplifies the spirit of innovation and dedication to improving healthcare through patented inventions. His contributions to the development of new compounds pave the way for future advancements in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…